August 19, 2025
Eagle Pharmaceuticals Announces 2025 Annual Meeting Date
WOODCLIFF LAKE, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced…
Pharmaceuticals, Biotechnology and Life Sciences
WOODCLIFF LAKE, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced…
First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after…
ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial…
Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an…
CRANBERRY TOWNSHIP, Pa., Aug. 15, 2025 (GLOBE NEWSWIRE) — Jabez Biosciences, Inc., a clinical-stage biopharmaceutical company dedicated to ushering in…
EMERYVILLE, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage…
Breakthrough Protein Phosphatase 2A inhibitor LB-100 Targets Ovarian Clear Cell Carcinoma, Advanced Soft Tissue Sarcoma, and MSS Metastatic Colon Cancer…
Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASHSOUTH SAN FRANCISCO, Calif.,…
SARASOTA, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) — INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare…
COSCIENS Board of Directors approves a plan to voluntarily delist from Nasdaq, while retaining the Company’s listing on the TSX…